DIRS.INFO The most relevant business & tech news

In a filing to Shanghai's stock exchange, CanSino said it would manufacture and supply unspecified mRNA products to AstraZeneca. AstraZeneca said the deal would support investigational mRNA vaccines in its early pipeline. The country approved in March its first homegrown mRNA vaccine against COVID, developed by CSPC Pharmaceutical Group (1093.HK). CanSino has been working on its own mRNA COVID vaccine, and said in February it was in discussion with Chinese regulators around the protocol for a late-stage study for its COVID mRNA booster vaccine, CS-2034. It also comes after vaccine maker Moderna (MRNA.O), which has said that it was keen to sell its mRNA vaccine to China, announced a deal last month to develop and manufacture mRNA medicines in the country.

Persons: Dado Ruvic, Biologics, CanSino, Wang Wentao, Casey Hall, Ludwig Burger, Miyoung Kim, Mark Potter, Himani Organizations: AstraZeneca, REUTERS, HK, CSPC Pharmaceutical, CS, Communist Party, China's Commerce, Moderna, Thomson Locations: Swedish, China, Frankfurt

☆ Disease prevention is very important
▼ + stars: | 2023-06-27 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDisease prevention is important, not just for children or the elderly: CanSino Biologics chairmanYu Xuefeng, Chairman of CanSino Biologics discusses post-pandemic future for the wider healthcare sector and defends fall in the firm's stock price.

Persons: CanSino, Yu Xuefeng, CanSino Biologics

☆ China is still racing to develop its own mRNA jabs. But they won't use foreign vaccines to fight COVID because of 'national pride,' says South Korea's top vaccine maker.
▼ + stars: | 2023-01-10 | by ( Huileng Tan | ) www.businessinsider.com time to read: +4 min

It hasn't yet approved any mRNA vaccines. But SK Bioscience says China is unlikely to source foreign COVID-19 vaccines, due to "national pride." SK Bioscience has developed its own COVID-19 vaccine, which is now being used in South Korea. "China has administered 3.4 billion doses of COVID vaccines for its people, covering over 90% of its population," said Liu. Even so, Chinese drugmakers are racing to produce mRNA vaccines against COVID-19.

☆ China's 'great migration' kicks-off under shadow of COVID
▼ + stars: | 2023-01-07 | by ( Casey Hall | ) www.reuters.com time to read: +6 min

BORDER REOPENINGSunday marks the reopening of China's border with Hong Kong and the end of China's requirement for inbound international travellers to quarantine. More than a dozen countries are now demanding COVID tests from Chinese travellers, as the World Health Organisation said China's official virus data underreported the true extent of its outbreak. In Shanghai, for example, the city government on Friday announced an end to free PCR tests for residents from Jan. 8. China has relied on nine domestically-developed COVID vaccines approved for use, including inactivated vaccines, but none have been adapted to target the highly-transmissible Omicron variant and its offshoots currently in circulation. China reported three new COVID deaths in the mainland for Friday, bringing its official virus death toll to 5,267, one of the lowest in the world.

☆ Chinese-made mRNA vaccine starts trial production
▼ + stars: | 2023-01-07 | by ( ) www.reuters.com time to read: +1 min

SHANGHAI, Jan 7 (Reuters) - China's CanSino Biologics Inc (6185.HK) has entered "test production phase" for its COVID-19 mRNA booster vaccine, the company said in a post on its social media account late on Thursday. The CanSino booster vaccine is one of China's first home-grown potential vaccines based on mRNA technology similar to that employed in vaccines produced internationally by Pfizer-BioNTech and Moderna. On Thursday, CanSino also reported "positive" interim data from a mid-stage clinical trial in a filing to the Hong Kong stock exchange. According to CanSino, the first phase of its mRNA vaccine production could produce 100 million doses. Reporting by Casey Hall; Editing by Jacqueline WongOur Standards: The Thomson Reuters Trust Principles.

☆ China-Developed mRNA Covid Vaccine Starts Test Production
▼ + stars: | 2023-01-06 | by ( Joyu Wang | ) www.wsj.com time to read: 1 min

TAIPEI—Chinese drugmaker CanSino Biologics Inc. started trial production of a vaccine targeting new variants of Covid-19 that are behind the country’s current outbreak, which would be among the first developed in China using the mRNA technology that drove inoculation in the U.S. and other countries. The Tianjin-based biotech firm plans to produce 100 million doses of the vaccine, designed to combat Omicron during the first phase of manufacturing, according to a company release posted to its social-media account late on Thursday.

☆ Factbox: China's rigid zero-COVID-19 policy starts to thaw
▼ + stars: | 2022-12-07 | by ( ) www.reuters.com time to read: +4 min

Beijing has not officially said it is ending its zero-COVID policy, but the adjustments are the clearest sign yet China is quickly pivoting away from that policy and towards letting its people live with the disease. Health officials are still warning that trends in fatalities will be closely watched in case a return to tougher measures is needed. Over the past few weeks, authorities have made varying policy changes in cities such as Guangzhou and Beijing, despite recent record infections. With jubilation, especially in big cities, frustrated by the inconvenience, uncertainty, economic toll and travel hurdles that came with zero-COVID. Also, time will tell with the winter flu season and the annual session of parliament that usually starts on March 5.

☆ Factbox: China's COVID-19 policy in flux
▼ + stars: | 2022-12-05 | by ( ) www.reuters.com time to read: +4 min

Here are questions and answers about a key turning point in President Xi Jinping's signature policy:IS CHINA ABANDONING ZERO-COVID? Changes varying by location have taken place even in cities such as southern Guangzhou and Beijing, the capital, despite recent record infections. Yet the current tally of 5,235 COVID-related deaths is a tiny fraction of China's population of 1.4 billion, and extremely low by global standards. Many, especially in big cities, frustrated by the inconvenience, uncertainty, economic toll and travel curbs accompanying zero-COVID, would welcome its end. Reporting by Beijing and Shanghai newsroom, Writing by Bernard Orr; Editing by Clarence FernandezOur Standards: The Thomson Reuters Trust Principles.

☆ CanSino rolls out inhalable COVID vaccine in Tianjin, Beijing
▼ + stars: | 2022-11-09 | by ( ) www.reuters.com time to read: +2 min

BEIJING, Nov 9 (Reuters) - Beijing residents can start making appointments for an inhalable COVID booster made by CanSino Biologics, media reported on Thursday, while those in Tianjin city can now get it as the Chinese pharmaceutical firm distributes more supplies. read moreThe financial hub of Shanghai and 13 cities in the eastern province of Jiangsu have already introduced the CanSino vaccine as a booster, the company said. Appointments for the vaccine in the capital can be booked on a mobile phone app for residents of one district, the official Beijing Business Daily reported on Thursday. China has relied on domestically produced, inactivated shots and has yet to import, or introduce its own version of an mRNA vaccine. Regarding the efficacy of its vaccine, Hong Kong-listed CanSino (6185.HK) said in a statement on Wednesday studies showed "using Convidecia Air as a heterologous booster generated much stronger immune responses than those induced by a homologous inactivated vaccine booster".

☆ CanSino's inhalable COVID-19 vaccines to be available in Tianjin from Nov 10
▼ + stars: | 2022-11-09 | by ( ) www.reuters.com time to read: 1 min

BEIJING, Nov 9 (Reuters) - Chinese pharmaceutical company CanSino Biologics (6185.HK) said on Wednesday its inhalable COVID-19 vaccines will be available in China's northern city of Tianjin from Nov 10, a statement on its Wechat account said. Last week, the Tianjin-based company said it did not expect its inhaled COVID vaccine to significantly boost financial results, based on current immunity strategy and domestic booster vaccination rates. China's financial hub Shanghai and 13 cities in eastern Jiangsu province have already introduced CanSino's inhalable vaccines as a booster for their citizens, CanSino said. Reporting by Ella Cao and Twinnie Siu. Editing by Jane MerrimanOur Standards: The Thomson Reuters Trust Principles.

☆ China posts 6-month high COVID count as it sticks with strategy
▼ + stars: | 2022-11-06 | by ( ) www.reuters.com time to read: +3 min

At a news conference on Saturday, health officials reiterated their commitment to the "dynamic-clearing" approach to COVID cases as soon as they emerge. China's anti-COVID measures are "completely correct, as well as the most economical and effective", said disease control official Hu Xiang. China's capital Beijing reported 43 symptomatic and six asymptomatic cases, compared with 37 symptomatic and five asymptomatic cases the previous day. Still, the annual Beijing marathon took place on Sunday morning under strict COVID protocols, after being cancelled the previous two years. Reporting by Ella Cao and Tony Munroe; Editing by Michael Perry and William MallardOur Standards: The Thomson Reuters Trust Principles.

☆ China rolls out first inhalable COVID vaccine
▼ + stars: | 2022-10-28 | by ( Casey Hall | ) www.reuters.com time to read: +3 min

Chinese regulators approved the vaccine, produced by Chinese pharmaceutical firm CanSino Biologics (6185.HK), for use as a booster in September. His hospital is among those administering the new vaccine, which will be used as well as regular injected shots. The country has relied on domestically produced, inactivated shots and has yet to import, or introduce its own version, of an mRNA vaccine. Loh is hopeful that results from Shanghai's foray into inhaled vaccines will encourage other countries to follow suit. "I think inhaled vaccines for respiratory illness like COVID-19 will be the future," he said.

☆ AstraZeneca's COVID vaccine suffers a setback in nasal spray trial
▼ + stars: | 2022-10-10 | by ( ) www.reuters.com time to read: +2 min

Also, the immune response measured in the blood was weaker than that from a shot-in-the-arm vaccination. India's health minister last month approved Bharat Biotech's COVID-19 nasal spray vaccine while China's CanSino Biologics Inc (6185.HK) last month won emergency approval by the country's drug regulator for an inhaled version of its COVID-19 vaccine. The British trial enrolled 30 previously unvaccinated participants as well as 12 volunteers, who had previously received a standard two-dose vaccine course by injection. "The nasal spray did not perform as well in this study as we had hoped," said Sandy Douglas, chief investigator of the trial at Oxford University's Jenner Institute. No serious adverse events or safety concerns were reported during the trial, which was funded by AstraZeneca, according to the statement.

☆ Как жителям Молдовы въехать в Грецию. Инструкция NM
▼ + stars: | 2021-06-21 | by ( ) newsmaker.md time to read: +1 min

Однако для жителей Молдовы это направление в большинстве случаев по-прежнему недоступно. NM рассказывает, при каких условиях все-таки можно попасть в Грецию. Жители Молдовы могут попасть в страну только если у них есть гражданство одной из стран союза (например, Румынии), либо соответствующий вид на жительство. Но даже в этом случае для въезда в Грецию нужно выполнить ряд условий. Кроме того, в пунктах пересечения границы Греции въезжающих могут дополнительно проверить на коронавирус.

Persons: Johnson, Janssen, Cansino Organizations: Pfizer, AstraZeneca, Sinovac Biotech, Gamaleya Locations: Moderna, Oxford, Novavax, Sinopharm, Греция, Молдова, ЕС, Румыния

☆ China a făcut peste un miliard de vaccinuri: Cum sunt convinși chinezii să se vaccineze
▼ + stars: | 2021-06-20 | by ( ) www.jurnal.md time to read: +3 min

Sursa foto: Profimedia ImagesChina a făcut peste un miliard de vaccinuri: Cum sunt convinși chinezii să se vaccinezeChina a depășit pragul de un miliard de doze de vaccin anti-COVID admninistrate, a anunţat duminică Ministerul Sănătăţii, fără a preciza însă procentul populaţiei care a fost vaccinată complet. Autoritățile folosesc tot felul de metode de a convinge populația să se vaccineze, până la stimulente constând în vouchere sau ouă. Un total de 1,01 miliarde de doze au fost deja administrate, a precizat Ministerul Sănătăţii de la Beijing. Iniţial, chinezii nu s-au grăbit să se vaccineze, deoarece virusul a fost practic eradicat din ţară de mai bine de un an, datorită carantinei obligatorii, a testelor masive şi a aplicaţiilor mobile pentru controlul călătoriilor. China speră să vaccineze cel puţin 70% din populaţia sa până la sfârşitul anului, adică aproximativ un miliard de persoane.

Organizations: China, Ministerul Sănătății, BioNTech Locations: China, Beijing, Guangdong, străinătate

☆ В Греции одобрили въезд привитых “Спутником V” туристов
▼ + stars: | 2021-06-12 | by ( Ольга Донцова | ) aif.md time to read: +1 min

0Национальный комитет по вакцинации в Греции одобрил въезд в страну туристов, привитых российской вакциной против коронавируса “Спутник V”. Папаевангелу сообщила, что на заседании комитета по вакцинации обсуждался опыт предыдущего туристического сезона и были обновлены соответствующие санитарные протоколы. По её словам, въезд туристов разрешён при условии, что все туристы старше 6 лет предоставляют или отрицательный ПЦР-тест, сделанный за 72 часа до прибытия в Грецию, либо свидетельство о вакцинации, либо свидетельство о недавно перенесённой болезни. В частности, мы утвердили вакцины Novavax, Sinovac/BioNTech, “Спутник (V)”, Sinopharm и Cansino Biologics, – сказала Папаевангелу. Греция с 14 мая открыла границы для туристов – отменены ограничения на въезд иностранных туристов, на карантин их помещать не будут.

Persons: “, Cansino, Папаевангелу Organizations: EMA, Национальный комитет по вакцинации, Афинский национальный университет имени Каподистрии Ван Папаевангелу, Национальный комитет, Европейское агентство по лекарственным средствам Locations: –, Греция, Европейский союз

☆ China se pregăteşte să vaccineze anti-COVID-19 copiii de peste trei ani
▼ + stars: | 2021-06-08 | by ( Publika.Md - Aici Sunt Știrile | ) www.publika.md time to read: +1 min

China se pregăteşte să vaccineze împotriva coronavirusului copiii de peste trei ani, a anunţat marţi o companie farmaceutică, ceea ce ar face din această ţară prima din lume care va distribui vaccinuri copiilor mici, informează AFP. „Vaccinul Sinovac a fost aprobat în ultimele zile pentru copiii cu vârste cuprinse între 3 şi 17 ani”, a declarat el pentru AFP, conform Agerpres. Purtătorul de cuvânt nu a precizat şi când ar putea fi administrate copiilor primele doze, de calendarul de vaccinare fiind responsabil Ministerul Sănătăţii. Laboratorul şi-a finalizat studiile clinice pe copii şi adolescenţi, iar rezultatele acestora vor fi publicate în revista britanică The Lancet, a adăugat el. Pe lângă Sinovac, China a aprobat până acum administrarea la adulţi a vaccinurilor produse de laboratoarele Sinopharm (două doze) şi Cansino Biologics (o doză).

Organizations: Agerpres Locations: China, Lancet, Sinovac

☆ Главы компаний Moderna и BioNTech стали долларовыми миллиардерами
▼ + stars: | 2021-05-24 | by ( ) nokta.md time to read: +1 min

Руководители компаний Moderna и BioNTech вместе с еще семью людьми, связанными с производством вакцин от коронавируса, стали долларовыми миллиардерами из-за роста прибыли их компаний на фоне всеобщей вакцинации от COVID -19. По подсчетам организации, состояние гендиректора американской компании Moderna Стефана Банселя выросло до 4,3 миллиарда долларов, а гендиректора немецкой BioNTech Угура Шахина — до 4 миллиардов, передает Настоящее время. Еще три новых миллиардера являются соучредителями китайской компании CanSino Biologics, выпускающей вакцину Convidicea. На нем в том числе обсуждался вопрос отказа от интеллектуальной собственности на антикоронавирусные вакцины. В поддержку временной приостановки действия патентов на вакцины выступают США, страны Европы высказываются против.

Persons: CanSino, nokta, Стефан Бансель, Угура Шахин, Тимоти Спрингер, Нубар Афеян, Хуан ЛопесБельмонте, Роберт Лэнджер Organizations: Oxfam —, Oxfam People Vaccineʼs Alliance, Oxfam, Vaccineʼs Alliance, ООН Locations: Moderna, —, Италия, США, Европа

☆ Главы компаний по производству COVID-вакцин стали миллиардерами – Цензура МД
▼ + stars: | 2021-05-24 | by ( ) cenzura.md time to read: +1 min

В мире Главы компаний по производству COVID-вакцин стали миллиардерамиРуководители компаний Moderna и BioNTech вместе с еще семью людьми, связанными с производством вакцин от коронавируса, стали долларовыми миллиардерами из-за роста прибыли их компаний на фоне всеобщей вакцинации от COVID -19. По подсчетам организации, состояние гендиректора американской компании Moderna Стефана Банселя выросло до 4,3 миллиарда долларов, а гендиректора немецкой BioNTech Угура Шахина — до 4 миллиардов, передает Настоящее время. Еще три новых миллиардера являются соучредителями китайской компании CanSino Biologics, выпускающей вакцину Convidicea. На нем в том числе обсуждался вопрос отказа от интеллектуальной собственности на антикоронавирусные вакцины. В поддержку временной приостановки действия патентов на вакцины выступают США, страны Европы высказываются против.

Persons: CanSino, Стефан Бансель, Угура Шахин, Тимоти Спрингер, Нубар Афеян, Хуан ЛопесБельмонте, Роберт Лэнджер Organizations: Oxfam —, Oxfam People Vaccineʼs Alliance, Oxfam, Vaccineʼs Alliance, Глава компаний, ООН Locations: Moderna, —, Италия, США, Европа

☆ Девять человек стали долларовыми миллиардерами на фоне всеобщей вакцинации от ковида
▼ + stars: | 2021-05-22 | by ( ) nokta.md time to read: +1 min

После начала пандемии коронавируса как минимум девять человек стали долларовыми миллиардерами из-за роста прибыли фармацевтических компаний, которые производят вакцины от ковида. Об этом сообщает Oxfam со ссылкой данные альянса правозащитных и медицинских организаций People Vaccineʼs Alliance. Среди новых миллиардеров наибольшее состояние у генеральных директоров американской компании Moderna Стефана Банселя (4,3 миллиарда) и немецкой BioNTech Угура Шахина (4 миллиарда), передает meduza. Отчет People Vaccineʼs Alliance был опубликован накануне Глобального саммита здравоохранения, прошедшего 21 мая в Италии. В поддержку временной приостановки действия патентов на вакцины выступают США, страны Европы высказываются против.

Persons: CanSino, nokta, Стефан Бансель, Угура Шахин, Тимоти Спрингер, Нубар Афеян, Хуан ЛопесБельмонте, Роберт Лэнджер Organizations: Oxfam People Vaccineʼs Alliance . Moderna, Moderna, Oxfam, Vaccineʼs Alliance, ООН Locations: Италия, США, Европа

☆ Руководители Moderna и BioNTech стали долларовыми миллиардерами на фоне вакцинации от COVID-19
▼ + stars: | 2021-05-22 | by ( ) newsmaker.md time to read: +1 min

С начала пандемии коронавируса как минимум девять человек стали долларовыми миллиардерами из-за роста прибыли фармацевтических компаний, которые производят вакцины от COVID-19. Об этом сообщила международная благотворительная организация Oxfam со ссылкой на данные People’s Vaccine Alliance, передает «Новая газета» 23 мая. xСреди тех, кто стал миллиардерами после начала всеобщей вакцинации, гендиректор американской компании Moderna Стефан Бансель (его состояние, по данным Oxfam, составило $4,3 млрд) и сооснователь и руководитель немецкой компании BioNTech Угур Шахин ($4 млрд). В список новых миллиардеров вошли еще четыре человека, связанных с Moderna — иммунолог Тимоти Спрингер ($2,2 млрд), председатель совета директоров Нубар Афеян ($1,9 млрд), руководитель компании, производящей упаковку для вакцины, Хуан Лопес-Бельмонте ($1,8 млрд) и инвестор Роберт Лэнджер ($1,6 млрд). Международная благотворительная организация Oxfam была основана в 1942 году.

Persons: CanSino, Стефан Бансель, Угур Шахин, Тимоти Спрингер, Нубар Афеян, Хуан ЛопесБельмонте, Роберт Лэнджер, Чжу Тао, Цю Дунсу, Мао Хуайхуа Organizations: Oxfam People’s Vaccine, Oxfam, Moderna, —, People Vaccineʼs Alliance, Новая газета Locations: Moderna, Италия

☆ Moldova urmează să inițieze procedura de achiziție a 400.000 de doze de vaccin CoronaVac, produs de SINOVAC
▼ + stars: | 2021-04-09 | by ( Publika.Md - Aici Sunt Știrile | ) www.publika.md time to read: +1 min

Astăzi, a avut loc ședința Comitetului de coordonare a imunizării împotriva COVID-19, în cadrul căreia a fost examinată oferta producătorului de vaccin împotriva COVID-19, SINOVAC BIOTECH LIMITED din China, singurul producător de vaccin care a răspuns solicitărilor adresate de către Centrul pentru Achiziții Publice Centralizate în Sănătate (CAPCS), producătorilor de vaccin.Astfel, în urma analizei ofertei, membrii Comitetului au decis contractarea directă a 400.000 doze de vaccin CoronaVac, produs de SINOVAC, după stabilirea tuturor condițiilor de contractare.Vaccinul CoronaVac este aprobat în 17 țări, inclusiv și în Ucraina. Vaccinul se administrează intramuscular, în 2 doze, la un interval de 28 de zile. Acesta se păstrează la temperatura de 2-8 grade Celsius.Până la ora actuală, CAPCS a lansat două proceduri de achiziție: negociere fără publicare prealabilă a anunțului de participare și licitație deschisă, în cadrul cărora nu a fost depusă nicio ofertă. Invitații au fost transmise producătorilor de vaccin împotriva COVID-19: Pfizer Inc, Moderna Inc, Johnson & Johnson Inc, AstraZeneca PLC, Sinopharm Group Co. Ltd, Russian Direct Investment Fund, Serum Institute of India, AstraZeneca/SK Bioscience Co.Ltd, Sinovac Biotech Ltd. și CanSino Biologics Inc.Menționăm că, CAPCS continuă negocierile directe, exclusiv cu producătorii de vaccin împotriva COVID-19, pentru asigurarea țării cu doze de vaccin în contextul implementării Planului național de imunizare împotriva COVID-19.

Persons: Johnson Organizations: Pfizer, Moderna Inc, Johnson Inc, Sinopharm Group, ., SK Bioscience Locations: China, Ucraina, India, SK Bioscience Co.Ltd, Ltd

☆ CAPCS urmează să inițieze procedura de achiziție a 400 000 de doze de vaccin CoronaVac, produs de SINOVAC BIOTECH LIMITED din China
▼ + stars: | 2021-04-09 | by ( Diana Severin | ) www.zdg.md time to read: +4 min

Ministerul Sănătății, Muncii și Protecției Sociale (MSMPS) anunță că vineri, 9 aprilie, a avut loc ședința Comitetului de coordonare a imunizării împotriva COVID-19, în cadrul căreia a fost examinată oferta producătorului de vaccin împotriva COVID-19, SINOVAC BIOTECH LIMITED din China. Potrivit MSMPS, acesta este singurul producător de vaccin care a răspuns solicitărilor adresate de către Centrul pentru Achiziții Publice Centralizate în Sănătate (CAPCS), producătorilor de vaccin. Astfel, în urma analizei ofertei, membrii Comitetului au decis contractarea directă a 400.000 doze de vaccin CoronaVac, produs de SINOVAC, după stabilirea tuturor condițiilor de contractare. Până la ora actuală, CAPCS a lansat două proceduri de achiziție: negociere fără publicare prealabilă a anunțului de participare și licitație deschisă, în cadrul cărora nu a fost depusă nicio ofertă. Licitația pentru procurarea dozelor de vaccin anti-COVID pentru utilizarea în cadrul planului național de imunizare COVID-19 a eșuat.

Persons: Johnson, MSMPS, CAPCS Organizations: Ministerul Sănătății, Muncii, Protecției Sociale, Pfizer, Moderna Inc, Johnson Inc, Sinopharm Group, ., SK Bioscience, Inc, Agenția Europeană, Organizației Mondiale a Sănătății Locations: China, Ucraina, India, SK Bioscience Co.Ltd, Ltd, Moldova

☆ В Молдове хотят закупить 400 000 доз вакцины CoronaVac производства SINOVAC
▼ + stars: | 2021-04-09 | by ( ) nokta.md time to read: +1 min

Руководящий комитет по координации иммунизации COVID-19 собрался сегодня, чтобы изучить предложение китайского производителя вакцины против COVID-19, SINOVAC BIOTECH LIMITED. По информации Минздрава, это единственный производитель вакцин, ответивший на запросы Центра централизованных закупок в области здравоохранения (CAPCS), производителей вакцин. Таким образом, после анализа предложения, члены Комитета приняли решение напрямую заключить контракт на 400 000 доз вакцины CoronaVac, производимой SINOVAC, после установления всех условий контракта. На сегодняшний день CAPCS запустила две процедуры закупок: переговоры без предварительной публикации уведомления о контракте и открытый тендер, в рамках которого не было подано никаких предложений. Приглашения были отправлены производителям вакцины против COVID-19: Pfizer Inc., Moderna Inc., Johnson & Johnson Inc., AstraZeneca PLC, Sinopharm Group Co. Ltd, Российский фонд прямых инвестиций, Индийский институт сыворотки, AstraZeneca / SK Bioscience Co.Ltd, Sinovac Biotech Ltd. и CanSino Biologics Inc.CAPCS продолжает прямые переговоры с производителями вакцины против COVID-19 о предоставлении стране доз вакцины в контексте реализации Национального плана иммунизации против COVID-19.

Persons: Johnson, CAPCS Organizations: Pfizer Inc, Moderna Inc, Johnson Inc, AstraZeneca PLC, Sinopharm, Ltd, AstraZeneca, SK Bioscience Co.Ltd, Sinovac Biotech, CanSino Biologics, Руководящий комитет, Минздрав, Центр централизованных закупок, Комитет, Российский фонд прямых инвестиций, Индийский институт сыворотки Locations: COVID, Украина

La ședința de astăzi a Comitetului de coordonare a imunizării împotriva COVID-19 a fost examinată oferta producătorului de vaccin împotriva COVID-19 Sinovac Biotech din China, în urma căreia s-a decis contractarea directă a 400 000 de doze de vaccin CoronaVac. Vaccinul CoronaVac este aprobat în 17 țări, inclusiv și în Ucraina. Vaccinul se administrează intramuscular, în 2 doze, la un interval de 28 de zile. Acesta se păstrează la temperatura de 2-8 grade Celsius. Până la ora actuală, CAPCS a lansat două proceduri de achiziție: negociere fără publicare prealabilă a anunțului de participare și licitație deschisă, în cadrul cărora nu a fost depusă nicio ofertă.

Persons: Johnson, Inc Organizations: Pfizer, Moderna Inc, Johnson Inc, Sinopharm Group, ., SK Bioscience Locations: China, Ucraina, India, SK Bioscience Co.Ltd, Ltd

Search resuls for: "CanSino Biologics"

25 mentions found